Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eugenia Page

Plastic Surgery Atlanta, GA Medical Doctor

NPI 1598925109 CMS profile 2307971

5673 Peachtree Dunwoody Rd Ste 870, Atlanta, GA 30342

Open in the dashboard

General payments

$8,044

308 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eugenia Page of Atlanta, GA is reported in the CMS Open Payments database as having received $8,044 across 308 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,496 85
2024 General $1,661 66
2023 General $1,987 59
2022 General $810 43
2021 General $806 43
2020 General $256 10
2019 General $29 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eugenia Page
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Eugenia Page were reported at $2,496. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Eugenia Page Plastic Surgery median Middle half National median
2019 $29 $371 $122–$1,483 $163
2020 $256 $158 $52–$438 $114
2021 $806 $249 $87–$752 $132
2022 $810 $274 $102–$793 $149
2023 $1,987 $299 $113–$891 $160
2024 $1,661 $361 $124–$1,062 $164
2025 $2,496 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mentor Worldwide LLC $3,645 100 payments
  2. AbbVie, Inc. $1,769 107 payments
  3. Integra LifeSciences Corporation $1,027 14 payments
  4. Allergan Inc. $554 48 payments
  5. Davol Inc. $266 4 payments
  6. TELA Bio, Inc. $132 7 payments
  7. Musculoskeletal Transplant Foundation Inc. $128 11 payments
  8. Biocircuit Technologies Inc $107 1 payment
  9. Kerecis Limited $101 1 payment
  10. Access Pro Medical, LLC $55 3 payments
  11. Other $262 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,718 307 payments
  2. Long term medical supply or device loan $326 1 payment
Products named General payments · program years 2019–2025
  1. MENTOR MemoryGel Resterilizable Gel Sizer $3,007 91 payments
  2. ALLODERM $1,363 79 payments
  3. DuraSorb Monofilament Mesh $624 3 payments
  4. SURGIMEND $403 11 payments
  5. Integra Recon-Skin And Wound $403 11 payments
  6. OMNIGRAFT $403 11 payments
  7. Integra Recon-Skin And Wound $403 11 payments
  8. INTEGRA DERMAL REGENERATION TEMPLATE $403 11 payments
  9. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $335 35 payments
  10. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $331 23 payments
  11. Other $2,290 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

193

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$1,161

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

18.7%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 36 $372
Gabapentin Generic 65 $304
Cefadroxil Generic 36 $187
Oxycodone Hcl Generic 35 $152
Methocarbamol Generic 21 $145

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$45,796

Medicare's payments for the services billed

Medicare patients

47

Average age 69

Services billed

166

47 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
Arthritis 43%
High blood pressure 40%
Osteoporosis 23%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record